Supplementary Table 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
Authors
Thomas H. A. Ederveen (ORCID: https://orcid.org/0000-0003-0068-1275)
Kalijn F. Bol (ORCID: https://orcid.org/0000-0003-4165-2040)
Supplementary Table 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
Thomas H. A. Ederveen, Kalijn F. Bol, Uta Flucke, Stefan G. van Ravensteijn et al.
Topics
Vascular Tumors and Angiosarcomas
article
Supplementary Table 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
Thomas H. A. Ederveen, Kalijn F. Bol, Uta Flucke, Stefan G. van Ravensteijn, Tessa J.J. de Bitter, Mark A.J. Gorris, Yvonne M.H. Versleijen‐Jonkers, Jacco J. de Haan, Suzanne E. J. Kaal, Melissa H.S. Hillebrandt-Roeffen, Hans A. J. Gelderblom, Carla M.L. van Herpen, Ingrid M.E. Desar, Annemarie Boleij, Minke Smits, Frank M. Speetjens, Maikel J.L. Nederkoorn, Han J. Bonenkamp, Alem Gusinac